Upload
sasaliu
View
236
Download
2
Embed Size (px)
Citation preview
8/2/2019 Focus on iVD
1/37
Woori Investment & Securities does not have a stake greater than or equal to 1% in companies mentioned in this material as of the preparation date. Woori I&S has not provided this material to an institutional investor or other third party in advance. The Korean version of this material was distributed on January 5, 2010. The analyst and his/her spouse do not own any securities of companies mentioned in this material as of the preparation date. Woori I&S is an issuer and LP (liquidity provider) of ELW taking Samsung Techwin as an underlying asset. Macrogen, Bionia, and Infopia are not under coverage at Woori I&S. Thus, Woori I&S does not present a rating and target price on the counter. This report correctly reflects the analysts opinion and was written without any external influence or intervention.
Domestic healthcare players go abroad
Global players such as Roche, J&J, and Siemens have entered the medical
equipment business, where operating margins exceed 20%.
We advise focusing on companies doing in-vitro diagnostics (IVD; large
overlap with equipment), given: 1) high operating margins; 2) strong growth
for the healthcare market (2008~2013 CAGR of 13.2%); and 3) an expected
surge in the medical equipment and diagnosis markets triggered by UShealthcare reform, which supports medical expenditures for the elderly.
Korean group companies to lead domestic healthcare market
The Samsung Group and SK Chemical have started to focus on healthcare
and biotech for three reasons. First, global healthcare expenditures continue
to grow. In particular, we expect 2010 total healthcare spending-to-GDP
ratios of 18.0% in the US, 10.6% in Germany, and 5.5% in Korea. Second,
demand for medical equipment grows as a population ages. Third,
technological improvement will likely lead to the creation of new markets.
Top picks: Samsung Techwin, SD
We recommend Samsung Techwin and Standard Diagnostics (SD) as our top
picks. We also expect rapid growth for Macrogen, which has core
competencies in personalized medicine.
Industry Analysis January 8, 2010
Bio/Healthcare Foc us on in-v i t ro d iagnost ic s
Rating and investment indices (Unit: won, %, x)
Op margin P/E P/B ROETicker Rating
Target price(12M)
Price(1/4) 2009E 2010F 2009E 2010F 2009E 2010F 2009E 2010F
SamsungTechwin
012450.KSBuy
(Maintain)120,000
(Maintain)91,000 8.1 7.9 26.6 17.4 4.5 3.6 17.3 22.6
SD 066930.KQBuy
(Initiate)38,000
(Initiate)32,300 45.3 42.2 8.3 6.9 3.3 2.3 47.9 39.1
Macrogen 038290.KQ NR NR 12,900 5.0 7.1 21.5 16.1 - - - -
Bionia 064550.KQ NR NR 5,900 25.0 25.8 10.8 9.2 - - - -
Infopia 036220.KQ NR NR 14,700 25.6 26.9 12.3 9.0 - - - -
Source: Woori I&S research center estimates
Analyst
Irene Kim822)768-7977, [email protected]
Susie Lee (RA)822)768-7646, [email protected]
Positive (Initiate)
8/2/2019 Focus on iVD
2/37
2
Bio/Healthcare www.wooriwm.com
Table of contents
I. Investment Summary ...................................................................................................
II. Valuation.......................................................................................................................
III. Healthcare to show high growth compared to other industries ............................
1. Healthcare market to post 2008~2013 CAGR of 13.2%
2. Focus on growth of IVD
3. Samsung and SK Chemical enter bio/healthcare
IV. Changing domestic and global diagnostics market ...............................................
1. Developed markets such as US, Europe leading global diagnostics industry
2. Domestic diagnostics overview
3. FDA approval to begin with 510k clearance
[Company Analysis]Samsung Techwin (012450.KS, Buy, TP W120,000) ...................................................
SD (066930.KQ, Buy, TP W38,000) ...............................................................................
Macrogen (038290.KQ, Not Rated) ...............................................................................
Bioneer (064550.KQ, Not Rated) ..................................................................................
Infopia (036220.KQ, Not Rated) ....................................................................................
3
5
10
16
22
28
33
35
36
8/2/2019 Focus on iVD
3/37
3
Bio/Healthcare www.wooriwm.com
I. Investment summary
The biotech industry, particularly healthcare, is expected to attract investor attention in 2010.
In particular, traditional pharmaceutical companies focusing on synthetic drugs face limited
growth due to lower chances of new drug development. Moreover, it has become more
difficult to gain FDA approval for new drugs. Thus, drug makers are shifting focus tobiodrugs instead of synthetic drugs.
Within the healthcare industry, investors have been less interested up to now in the non-
pharmaceutical sectors. But while pharmaceutical companies have enjoyed lofty operating
margins, structural changes are underway in the market amid the absence of new drug
development and intensifying competition.
Diagnosis market to
grow on US
healthcare reform
In addition to traditional pharmaceuticals, we note that medical equipment is also profitable.
Roche, J&J, GE, Siemens, and Abbott have diversified into the medical equipment market,
where operating margins are over 20%.
Healthcare reform has been a major political issue in the US, and we expect reform to drive
the growth of the global medical equipment and diagnostic markets. In particular, the US is
stressing the need for government intervention in the healthcare industry, with policy
measures including promoting the use of generic drugs and nurturing the medical
equipment/diagnostic markets to reduce chronic diseases in the elderly. In addition, because
of the lack of public healthcare coverage, 16% of the US population (46.60mn) is not covered
by health insurance.
Focus on companies
with biodrug
pipelines, medicalequipment plays
Of the many biotech companies, only a few have both technology and marketing capability.
New drug development is almost impossible for them without licensing-out due to the
massive capital needed. As such, we recommend screening biotech companies for playsboasting competitive drugs and equipment protected by patents.
Top picks: Samsung
Techwin, SD
Biotech/healthcare companies look attractive. The value chain of the healthcare industry is
prevention diagnosis treatment management, and we see promising companies
in each link of the chain. For biodrug makers, we note that it is critical to select the right sales
partner. Once biotech companies succeed in developing new drugs and/or biodrugs, the
markets interest tends to shift interest to the distribution partner. For biotech companies, the
selection of distribution partner is important, as this decision can affect sales growth and
market share. In this regard, we recommend Samsung Techwin and Standard Diagnostics
(SD) as our top picks, partly due to their successful track records in selecting partners. In
addition, we also maintain a positive view on Macrogen, which should also grow rapidly
based on its core competencies in individualized prescription.
8/2/2019 Focus on iVD
4/37
4
Bio/Healthcare www.wooriwm.com
Samsung Techwin:
transforming into a
healthcare play
Samsung Techwin has a traditional cash cow (defense business) and has recently secured a
new growth driver in its security equipment business. However, 4Q09 earnings are believed
to be disappointing due to performance bonus payments and a higher-than-expected
acquisition price for its CCTV division. On the upside, Techwin has prepared entry into new
growth businesses, such as robotics, biotech, and healthcare, and these new businesses are
expected to generate meaningful sales from 2010. Key investment points for Techwin are asfollows: 1) it should be the primary beneficiary of the Samsung Groups biotech and
healthcare business initiatives; 2) it is expected to take over Samsung Electronics security
equipment division; and 3) it boasts stable cash cows, such as its power system and defense
businesses.
SD: strong player in
rapid testing
Standard Diagnostics (SD) is a specialized virus diagnostics company, and its core business is
rapid test kits based on blood samples. The companys rapid test kit diagnoses antibodies or
antigens, which are markers of specific diseases. Currently, it sells rapid test kits for AIDS,
malaria, and hepatitis B. SD is capable of producing the antibodies and antigens used for the
rapid test kits internally, which not only shows its technological prowess but also gives it a
competitive edge in pricing. Key investment points for SD are: 1) it is the leading player in
rapid test kits; 2) it is expected to advance into developed markets following the expiry ofInverness patent; and 3) it has been successful in R&D in biochips and molecule diagnostics.
Macrogen: leader in
consumer genomics
Macrogen, a genetic diagnostics company, was listed in 2000. Following completion of the
Human Genome Project in 2007, the company set a new paradigm in information medicine,
and is expected to emerge as a leader in the personalized medicine market based on its
strength in genetics. In 2000, when genomic medicine was just getting started, genome
analysis per person would have cost more than US$3bn, but the cost has plummeted and
should reach US$1,000/person in 2010 thanks to advancing gene sequencing technology. The
drop in cost should lead to explosive growth in personalized medicine business. Currently, the
personalized medicine market is estimated at US$232bn, but should grow more than 11% per
annum going forward. Key investment points for Macrogen are as follows: 1) it is a leader in
consumer genomics; 2) it is the only downstream company in Korea in the personalizedmedicine business; and 3) it has made investments in a global sequencing equipment
company to better position itself in the personalized medicine market.
Recommendations (Units: won, %, x)
OP margin P/E P/B ROECode Rating
Target price(12M)
Currentprice(1/4) 2009E 2010F 2009E 2010F 2009E 2010F 2009E 2010F
SamsungTechwin
012450.KSBuy
(Maintain)120,000
( Maintain )91,000 8.1 7.9 26.6 17.4 4.5 3.6 17.3 22.6
SD 066930.KQ Buy(Initiate) 38,000( Initiate ) 32,300 45.3 42.2 8.3 6.9 3.3 2.3 47.9 39.1
Macrogen 038290.KQ Not Rated Not Rated 12,900 5.0 7.1 21.5 16.1 - - - -
Bioneer 064550.KQ Not Rated Not Rated 5,900 25.0 25.8 10.8 9.2 - - - -
Infopia 036220.KQ Not Rated Not Rated 14,700 25.6 26.9 12.3 9.0 - - - -
Source: Woori I&S Research Center estimates
8/2/2019 Focus on iVD
5/37
5
Bio/Healthcare www.wooriwm.com
II. Valuation
We initiate coverage on SD with a Buy rating and target price of W38,000. Meanwhile, we
note that Samsung Techwin is already under our coverage under its traditional categorization
as a tech stock, but in this report, we take a closer look at Techwins prospects in healthcare.
Mindray enjoying
45% premium to
sector average
Our target was derived via RIM valuation.
For comparison purposes, we note that there is no suitable comparable for SD or Techwin in
Korea due to the healthcare industrys short history. Looking overseas, we think Mindray
(China) is a good comparable for Samsung Techwins healthcare business model. Following
the financial crisis, the healthcare sector has traded at a 16% discount to the MSCI US
market, while Mindray has enjoyed a 45% premium to the sector thanks to its pronounced
top- and bottom-line growth.
We believe Techwin is a similar case, boasting stable operations, strong margins, and growth
potential. Currently, shares are trading at a 2010 P/E of 17x, vs the Kospi of 10x. We believe
it merits a premium given: 1) a three-year-forward EPS CAGR of 37.1%, higher than peers;
2) synergy with the robotics division following the acquisition of its security & imaging
business; and 3) the growth potential of the robotics and healthcare businesses.
Similarly, SD also boasts strong margins. The company sells rapid diagnostic kits at 200
agencies in 105 countries worldwide, and is set to tap into advanced markets in 2010. Shares
are trading at a 2010 P/E of only 6.9x (EPS of W4,713), and thus, offer strong upside, in our
view.
8/2/2019 Focus on iVD
6/37
6
Bio/Healthcare www.wooriwm.com
US healthcare relative to MSCI US
60
70
80
90
100
110
120
'06.1 '07.1 '08.1 '09.1
-60
-45
-30
-15
0
15
30
MSCI US Healthcare (LHS)
Relative return to MSCI US (RHS)
(2006.1 =100)
Source: Datastream, Woori I&S Research Center
Mindray enjoys 45% premium to sector average
0
10
20
30
40
50
'06 '07 '08 '09
MSCI US - P/E
MSCI US. Healthcare - P/E
Mindray- P/E
(x )
Source: Datastream, Woori I&S Research Center
8/2/2019 Focus on iVD
7/37
7
Bio/Healthcare www.wooriwm.com
Investment indicators for domestic healthcare playersSamsungTechwin
SD Macrogen Bioneer Infopia Nano EnTek
Core biz Electronics Pharma Pharma Pharma Pharma Pharma
Rating Buy Buy Not Rated Not Rated Not Rated Not RatedCode 012450.KS 066930.KQ 038290.KQ 064550.KQ 036220.KQ 039860.KQ
Current price (Jan 4, won) 91,000 32,300 12,900 5,900 14,700 5,240
Market cap (Wbn) 4,384.8 258.4 64.6 67.0 109.3 92.5
Beta (2-yr weekly) 0.93 0.91 0.99 1.18 1.39 1.15
Sales 2008 2,339.6 40.3 16.5 14.9 37.2 6.4
(Wbn) 2009E 2,652.0 64.3 - - - -
2010F 3,237.0 82.4 - - - -
Op prof 2008 146.9 14.2 -1.1 -0.3 11.2 -1.6
(Wbn) 2009E 214.1 29.1 - - - -
2010F 254.6 34.8 - - - -
EPS 2008 956 1,091 35 -314 747 -311
(won) 2009E 3,553 3,828 - - - -
2010F 5,232 4,713 - - - -EPS growth 2008 -63.8 3.5 TTP RR -41.2 RR
(% y-y) 2009E 271.6 250.8 - - - -
2010F 47.3 23.1 - - - -
Op margin 2008 6.3 35.2 -6.5 -2.3 30.2 -24.9
(%) 2009E 8.1 45.3 - - - -
2010F 7.9 42.2 - - - -
Net margin 2008 3.1 21.6 1.1 -23.9 14.9 -85.0
(%) 2009E 7.1 47.7 - - - -
2010F 8.6 45.7 - - - -
ROE 2008 7.0 18.3 0.5 -10.1 12.0 -24.9
(%) 2009E 17.3 47.9 - - - -
2010F 22.6 39.1 - - - -
P/E 2008 35.8 8.3 268.2 NA 15.1 NA(x) 2009E 26.6 8.3 - - - -
2010F 17.4 6.9 - - - -
P/B 2008 2.5 1.5 1.5 0.8 1.9 2.0
(x) 2009E 4.5 3.3 - - - -
2010F 3.6 2.3 - - - -
Source: annual reports, , Woori I&S Research Center estimates
Investment indicators for domestic healthcare players (1): 2010 P/E and EPS growth
SD
Samsung Techwin
Roche SiemensJ&J
Beckman CoulterBio Merieux
BayerInverness
Becton Dickinson
Abbott
5
10
15
20
25
0 10 20 30 40 50
(EPS growth, %)
(PER, x)
Source: Bloomberg, Woori I&S Research Center estimates
8/2/2019 Focus on iVD
8/37
8
Bio/Healthcare www.wooriwm.com
Investment indicators for overseas healthcare playersRoche Siemens Abbott J&J
BeckmanCoulter
Bio Merieux BayerBecton
DickinsonInverness
Country Switzerland Germany US US US France Germany US US
Ticker (Bloomberg) RO SW SIE GY ABT US JNJ US BEC US BIM FP BAYN GY BDX US IMA USCurrent price (Jan 4, $) 174.5 91.8 54.0 64.4 65.4 116.7 80.0 78.9 41.5
Market cap ($mn) 146,987.9 83,880.8 83,508.4 177,713.6 4,537.0 4,604.9 66,126.1 18,699.2 3,454.2
Beta (2 weekly) 0.85 1.09 0.62 0.68 0.76 0.68 0.81 0.65 1.02
Sales 2008 39,494.6 103,865.1 29,622.8 64,469.5 3,097.8 1,428.2 41,336.6 7,160.9 1,660.3
($mn) 2009E 47,928.6 104,827.6 30,524.5 61,096.1 3,237.5 1,762.9 45,030.3 7,593.5 1,983.8
2010F 48,709.1 108,691.2 33,083.5 64,040.3 3,766.4 1,894.2 46,995.5 8,053.3 2,210.3
Op prof 2008 12,529.2 7,768.4 6,361.1 16,467.9 341.7 226.2 5,334.2 1,650.4 329.8
($mn) 2009E 13,774.3 7,586.0 7,205.0 16,767.9 406.3 298.5 5,298.6 1,709.1 464.2
2010F 15,934.4 9,515.1 7,978.1 17,888.2 515.9 328.0 6,555.7 1,845.8 539.0
EPS 2008 10.0 3.6 3.3 4.5 3.6 3.9 4.9 5.1 2.0
($) 2009E 11.6 5.9 3.7 4.6 3.9 5.2 4.8 5.1 2.6
2010F 13.0 7.6 4.2 4.9 4.5 5.8 5.7 5.6 3.0
EPS growth 2008 -8.2 -58.7 35.0 25.9 -8.9 32.7 -62.0 11.1 -(% y-y) 2009E 16.0 63.9 12.1 2.2 8.3 33.3 -2.0 0.0 30.0
2010F 12.1 28.8 13.5 6.5 15.4 11.5 18.8 9.8 15.4
Op margin 2008 31.7 7.5 21.5 25.5 11.0 15.8 12.9 23.0 19.9
(%) 2009E 28.7 7.2 23.6 27.4 12.5 16.9 11.8 22.5 23.4
2010F 32.7 8.8 24.1 27.9 13.7 17.3 13.9 22.9 24.4
Net margin 2008 21.7 3.0 17.5 19.9 7.1 10.9 7.7 17.2 9.6
(%) 2009E 20.2 4.6 18.9 20.9 8.0 11.6 7.1 16.2 12.2
2010F 23.1 6.0 19.4 21.3 8.5 12.0 8.6 16.6 12.8
ROE 2008 20.8 8.6 26.1 28.1 14.6 18.5 14.3 24.4 0.1
(%) 2009E 36.8 11.8 30.3 27.3 14.6 19.2 13.0 22.2 7.1
2010F 127.8 14.7 28.6 27.0 14.5 18.5 15.0 20.6 8.4
P/E 2008 17.5 24.5 16.2 14.2 18.3 29.7 16.4 14.1 21.2
(x) 2009E 15.0 15.6 14.5 14.1 17.0 22.5 16.6 15.5 16.0 2010F 13.4 12.1 13.0 13.1 14.5 20.3 14.1 14.2 13.9
P/B 2008 3.5 2.1 4.0 3.9 2.6 5.3 2.9 3.2 1.2
(x) 2009E 32.1 1.9 4.0 3.7 2.2 4.1 2.5 3.2 1.0
2010F 13.7 1.7 3.4 3.2 1.9 3.6 2.3 2.8 1.0
Source: Bloomberg, Woori I&S Research Center
Investment indicators for overseas healthcare players (1): 2010 P/B and ROE
Roche (13.7, 127.8)
Siemens
Abbott
J&J
Beckman Coulter
Becton Dickinson
Inverness
Bio MerieuxBayer
0
6
12
18
24
30
0.0 0.8 1.6 2.4 3.2 4.0
(ROE, %)
(PBR, x)
Source: Bloomberg, Woori I&S Research Center estimates
8/2/2019 Focus on iVD
9/37
9
Bio/Healthcare www.wooriwm.com
Peer analysis domestic healthcare share performanceSamsungTechwin
SD Macrogen Bioneer Infopia Nano EnTek
Current price (Jan 4, won) 91,000 32,300 12,900 5,900 14,700 5,240
Market cap (Wbn) 4,384.8 258.4 64.6 67.0 109.3 92.51 week -3.2 1.1 11.2 4.9 1.0 6.2
1 month -13.2 7.2 14.9 27.2 8.2 29.2
3 month -6.6 11.9 -0.3 25.0 14.7 0.7
6 month 10.2 17.5 -43.8 23.1 -34.2 -23.8
1 year 86.9 141.0 12.1 166.8 -14.9 63.2
Relative (%)
Ytd -2.2 0.6 16.5 5.0 0.6 7.5
1 week 2.9 2.7 4.0 5.4 5.0 -3.7
1 month -7.9 11.8 9.8 27.0 15.7 26.7
3 month -11.5 26.9 -3.7 21.3 24.1 -0.9
6 month -18.4 40.1 -38.6 40.6 -19.5 -14.5
1 year 12.6 250.3 50.2 268.8 26.8 132.9
Absolute (%)
Ytd 0.2 1.3 7.5 1.2 3.9 1.7
Source: Bloomberg, Woori I&S Research Center
Global peer analysis overseas healthcare share performanceRoche Siemens Abbott J&J
BeckmanCoulter
Bio Merieux BayerBecton
DickinsonInverness
Current price (Jan 4, $) 174.5 91.8 54.0 64.4 65.4 116.7 80.0 78.9 41.5
Market cap ($mn) 146,987.9 83,880.8 83,508.4 177,713.6 4,537.0 4,604.9 66,126.1 18,699.2 3,454.2
1 week 1.5 1.9 0.1 -0.5 1.1 0.0 1.0 -1.2 -2.4
1 month 5.3 -0.8 -1.1 -1.9 -1.7 -2.4 1.0 -1.7 -1.9
3 month 0.7 -1.5 -0.6 -0.7 -8.0 2.2 10.9 7.3 -1.9
6 month -3.7 7.6 -6.9 -8.6 -4.0 2.3 17.4 -9.9 -1.2
1 year -6.1 -1.7 -15.3 -11.8 24.4 12.8 8.5 -6.9 63.1
Relative (%)
Ytd 0.7 0.4 -0.7 -1.2 1.3 0.3 -0.7 -1.9 0.2
1 week 2.2 2.6 0.6 0.0 1.5 1.7 1.8 -0.8 -2.0
1 month 7.4 3.1 1.3 0.5 0.7 1.9 5.0 1.2 0.5
3 month 8.7 8.8 10.2 9.1 1.3 12.1 24.0 17.3 9.1
6 month 19.6 38.2 19.7 17.4 21.9 31.7 50.8 14.9 24.8
1 year 13.1 22.0 5.1 10.2 52.2 34.1 36.7 14.7 105.0
Absolute (%)
Ytd 2.0 2.0 0.9 0.4 2.9 2.2 0.8 -0.3 1.8
Source: Bloomberg, Woori I&S Research Center
Global peer analysis market valuation (Units: x, %) Kospi Dow Jones Shanghai Taiwan FTSE CAC
2008 10.0 13.9 17.6 22.5 24.7 9.0
2009 10.35 16.46 19.26 24.83 15.24 12.38P/E
2010 9.12 11.80 16.07 17.16 12.21 10.30
P/S 2010 0.69 1.17 1.65 - 1.02 0.79
P/B 2010 1.14 2.27 2.47 2.15 1.78 1.27
P/cash 2010 5.90 7.83 6.02 2.44 6.45 5.59
EV/EBITDA 2010 7.08 7.37 6.38 - 10.29 16.62
Div yield 2010 1.73 2.95 2.00 7.58 4.05 4.37
Source: Bloomberg, Woori I&S Research Center
8/2/2019 Focus on iVD
10/37
10
Bio/Healthcare www.wooriwm.com
III. Healthcare to show high growth compared to other industriesHealthcare
outperforms other
sectors
Since 1990, the S&P500s cumulative returns by sector break down as follows: healthcare
290%, IT 272%, energy 271%, and the overall S&P500 126%, clearly indicating healthcares
exceptional return. But though the pharmaceutical industry has driven growth up to now,
public health insurance is financially strapped due to the growth of chronic illnesses resultingfrom an aging population, coupled with increased medical spending by the elderly.
Accordingly, we believe investors should focus more on prevention and diagnosis than
treatment.
Overall, we believe the healthcare industry will continue to expand thanks to: 1) the growth
of chronic illnesses in line with the aging of the population; and 2) rising per-capita medical
spending. In addition, we note that along with pharmaceuticals, medical equipment is also
enjoying high margins, and has already seen the entry of several large global players.
Moreover, the diagnostic industry should show high growth given the following:
- the healthcare market is expected to post a 2008~2013 CAGR of 13.2%;
- increasing demand for in-vitro diagnostics (IVD), which can has many applications;
- Samsung and SK Chemical will likely accelerate their entries into new growth industries,
including biotech and healthcare.
Healthcare outperformed other sectors (in terms of cumulative returns)
0 100 200 300 400
Healthcare
IT
Energy
Cons.
S&P 500
Cons. Disc.
Industrials
Materials
Financials
UtilitesTelecom
(% )
0 2 4 6 8
Healthcare
IT
Energy
Cons.
S&P 500
Cons. Disc.
Industrials
Materials
Financials
UtilitesTelecom
(% )
Note: Dec 31, 1989~Mar 31, 2009Source: Industry data, Woori I&S Research Center Note: Dec 31, 1989~Mar 31, 2009Source: Industry data, Woori I&S Research Center
8/2/2019 Focus on iVD
11/37
11
Bio/Healthcare www.wooriwm.com
1. Healthcare market to post 2008~2013 CAGR of 13.2%
Healthcare market to
post 2008~2013
CAGR of 13.2%
Global healthcare market has expanded sharply, from US$306.5bn (W368tn) in 2000 to an
estimated US$928.2bn (W1,114tn) in 2009, for a CAGR of 13.2%. The global healthcare
market is steadily growing on rising demand for medical services in line population aging in
many major markets. We believe the biotech/healthcare market has brighter growth prospectsthan the traditional pharmaceutical market (growth estimated in the 5% range).
The healthcare industry includes drugs, medical equipment, medical services, and other
medical goods. In Korea, the healthcare industry comprises only 1.6% of total stock market
capitalization, vs 20% in the US and 13% in Japan. Although Koreas medical service market
is in its fledgling stages, it is expected to grow when life insurers go public. In particular, we
expect the Korean healthcare industrys market cap to increase following the listing of life
insurers such as Tongyang Life (2009), Samsung Life (2010), and Korea Life in (2010).
US healthcare spending rising sharply
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
1965 1969 1973 1977 1981 1985 1989 1993 1997 2001 2005 2009E 2013E 2017E
National Health Expenditures
($bn)
Healthcare spending up sharply following inflation
2008 ~2013 CAGR estimated at 6.2%
Source: Woori I&S Research Center
Healthcare spending to steadily increase
0
2,000
4,000
6,000
8,000
10,000
12,000
1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2015
China Germany
India Korea
Switzerland UK
US
Health
expenditure
percapital
(US$)
It's time for Korea seek to
increase healthcare spending
US seeks to reduce healthcare spending
Source: Datamonitor, Woori I&S Research Center
8/2/2019 Focus on iVD
12/37
12
Bio/Healthcare www.wooriwm.com
2. Focus on growth of IVD
Medical equipment
boasts lofty
operating margins
In the healthcare industry, medical equipment boasts the second-highest operating margins,
following pharmaceutical products. Given that the medical equipment business requires R&D
and massive capital, global leaders maintain oligopolies in developed markets such as the US
and Europe.
We expect the genetic diagnosis market (which overlaps substantially with the equipment
market) to grow in line with the expansion of personalized medicine. In particular, the genetic
diagnostic market is enjoying rapid growth amid rising demand for PCR (polymerase chain
reaction) equipment. For example, global leaders are accelerating their R&D efforts for the
diagnosis of critical illnesses.
Genetic diagnosis
growing rapidly
Diagnosis is largely based on tests using urine, blood, or genetic material (PCR). Sensitivity
and accuracy are lower for urine- and blood-based tests than genetic tests, and sensitivity of
rapid diagnostic kits is far lower than that of traditional PCR. Thus, we believe there would
strong demand for a fast PCR-based kit.
Going forward, when mass production of biochips and DNA chips becomes possible, we
expect the diagnostics market to show explosive growth. One shortcoming of biochip kits is
low sensitivity because of difficulty in protein amplification. The key features of a diagnostic
kit should be high sensitivity, accuracy, price competitiveness, reproducibility, automatability,
and short response time.
Medical equipment market classification: Korean companies competitive in IVD, imaging diagnostics, and dental equipment
PI&D SI&S EMI R&I IVD Other Dental
Definition
Medical equipmade forspecific purpose
Surgery equipand commoditiesused in alldivisions
Electronic medicalequipment usedfor treatment/surgery
Imaging devicesused fordiagnosingdisease
Diagnose diseaseby using bodilyfluid or cells
Aid for bodilyfunctions; simpletesters
Dental equipment
Major
products
Stent, catheter Artificial knee/joint
Bandage, thread Surgical knife,
needle Syringe, surgical
gloves
Hemodialyzer Patient monitoring
system
X-Ray, CT, MRI, Ultrasound
Blood sugar tester Immune tester Nucleic acid
tester
Wheelchair, bed Hearing aid Apnea monitoring
device
Chair Electric hand
piece Artificial tooth
Note: Global 2008 medical equipment market US$280bn
Source: Woori I&S Research Center
8/2/2019 Focus on iVD
13/37
13
Bio/Healthcare www.wooriwm.com
IVD market to grow at CAGR of 7% from US$40bn in 2008
0
10
20
30
40
50
60
2003 2004 2005 2006 2007 2008 2009E 2010F 2011F 2012F 2013F
MDx market
IVD market
($bn)
IVD market to grow to US$52bn by 2013 (2009 ~13 CAGR of, 5%);
gene teic diagnostics to reach US$5.9bn (2009~1 3 CAGR of 15%)
Source: Datamonitor, Woori I&S Research Center
Gene diagnostics market to expand at 2009~2013 CAGR of 15%
Blood cell calculatorBlood clotting tester
Example
Analyze number/shape of red &white blood cells, platelets
Definition
Blood analysis
Blood sugar testerUrine tester
Example
Analyze chemical compoundsof small molecules for bloodsugar, PH, and drug levels
Definition
Clinical chemistry
Incubator
Example
Analyze drug sensitivity viagerms and parasites, for
epidemics
Definition
Micro-organismanalysis
Automatic immune analyzer
Example
Diagnose hormone balance ordisease using antigen-antibodyreaction test on biopolymer (eg,
hormone or phatogen)
Definition
Immune analysis
MicroarrayPCR
Example
Diagnose disease (inclepidemic, cancer) or diseaseprogress by decoding target
chromosome/nucleic acid rank
Definition
Gene analysis
New IVDTraditional IVDs
Blood cell calculatorBlood clotting tester
Example
Analyze number/shape of red &white blood cells, platelets
Definition
Blood analysis
Blood sugar testerUrine tester
Example
Analyze chemical compoundsof small molecules for bloodsugar, PH, and drug levels
Definition
Clinical chemistry
Incubator
Example
Analyze drug sensitivity viagerms and parasites, for
epidemics
Definition
Micro-organismanalysis
Automatic immune analyzer
Example
Diagnose hormone balance ordisease using antigen-antibodyreaction test on biopolymer (eg,
hormone or phatogen)
Definition
Immune analysis
MicroarrayPCR
Example
Diagnose disease (inclepidemic, cancer) or diseaseprogress by decoding target
chromosome/nucleic acid rank
Definition
Gene analysis
New IVDTraditional IVDs
Source: Woori I&S Research Center
Diagnostic chip overview
Used for diagnosing disease by detecting RNA from a cell by fixing DNA
Application Detect RNA (from blood) related to a specific diseaseDNA chip
Technology DNA chip used for gene expression or reagent development research
Used for confirming disease or screening reagentApplication
Detect protein or biopolymer that interacts with a certain protein by fixing proteinProtein chip
Technology Protein chips can detect protein using small sample, but commercialization hindered by difficulties in amplifying protein
Application Detect and trigger diverse chemical reactions by forming a circuit on a chip
Applicable to diverse fields, including diagnosis, environmental monitoring, and food testing
LOC has more diverse applications than DNA chip, but suffers issues in production (plastic injection)
Lab-on-a-chip(LOC) Technology
If technology becomes fully developed, LOC likely to beat DNA chips
Source: Woori I&S Research Center
8/2/2019 Focus on iVD
14/37
14
Bio/Healthcare www.wooriwm.com
3. Samsung and SK Chemical enter bio/healthcareSamsung and SK
Chemical enter
healthcare business
Large players, including the Samsung Group and SK Chemical, are diversifying into the
healthcare/bio business. We expect rapid growth for the domestic healthcare industry.
In Oct 2007, the Samsung Group selected bio/healthcare (including medical equipment) as
one of its six new growth drivers, and mid- to long-term investment is underway. Samsung is
likely to enter the personalized medicine market to cure terminal illnesses, including cancer.
Personalized medicine is expected to grow at more than 11% per annum (up from
US$232.0bn in 2009. The Samsung Medical Center will do R&D and the Samsung Cancer
Research Institute will develop treatments for terminal illnesses. The Institute appointed Dr
Sun-myung Paek, who successfully commercialized a breast cancer diagnosis kit (Oncotype
DX), as head of the institute, and development of cancer targeting therapy is underway.
Meanwhile, SK Chems entry into the healthcare business began in 2008 with the takeover of
Ubicare, and its pharmaceutical division has been attracting attention since 2007 due to its
operating profit contribution. However, sales dropped in 2008 as the divisions flagship drugswere excluded from insurance coverage and sales of new drug Mvix disappointed. The
company was able to offset sluggish sales with the licensing-out of new drug projects. We
believe SK Chem will be able to pay down debt using cash from the disposal of its stake in
SK E&C (40%) and land in Suwon. While cash flow should improve from the disposal of the
stake in the construction affiliate, it is likely to hurt asset value.
We expect SK Chems green chemical division to enter new businesses such as biodiesel.
In addition, the pharmaceutical division aims to diversify into vaccines and healthcare. The
company may adjust its strategic approach in line with the Samsung Groups progress in
entering the biotech and healthcare businesses.
8/2/2019 Focus on iVD
15/37
15
Bio/Healthcare www.wooriwm.com
Diagnostics business essential for personalized medicine market growth
Pre-disease
/disease developmentHealth outcome
Primary riskassessment
Diagnosis Prognosis Drug selec tion Disease monitoring/management
Personalized medicine = using diagnostic tools for drug selectionand disease monitoring/management
Pre-disease
/disease developmentHealth outcome
Primary riskassessment
Diagnosis Prognosis Drug selec tion Disease monitoring/management
Personalized medicine = using diagnostic tools for drug selectionand disease monitoring/management
Source: Datamonitor, Woori I&S Research Center
Samsungs biotech & healthcare push, led by SEC, Techwin, Samsung Medical Center
Overview
- Samsung Medical Ctr system launches Aug 1, 2008- SMC becomes control tower for Samsung Groups
medical/bio-tech-related companies
Background
Focus on healthcare, a next-generation growth driverOrganic combination of medical treatment, research,
and education to maximize synergies in clinical testing
and medical business
Constituents
- Medical treatmentSamsung Seoul Hospital, Gangbuk Samsung
Hospital, Masan Samsung Hospital
- ResearchSamsung Biomedical Research Institute, Samsung
Cancer Research Center, IN-SUNG Foundation For
Medical Research, Samsung Mental health institute
- EducationSungkyungkwanUniversity School of Medicine
Medical commoditiesMedical commodities
Samsung Medical Center
Policyholders: 18.6mn Sales: W25tn
Eight hospitals (in Korea,overseas) including SMC
Hospitals
Construction
5 hospital groups(composed of 26 hospitals)
40 general hospitals
Biosimilar government projectsubmitted (Jun 2009)
SEC consortium SEC andother companies
Digital X-ray Detectormass production (2007)
Blood test equipmentdevelopment (2007)
Gene analysis equipmentdevelopment (2007)
Medical equipmentMedical equipment
MedicineMedicine
IT InfraIT Infra
InsuranceInsurance
Medical
expense
Products
Infra
SamsungSDI
Samsung Medical
Center
SEC
SECSamsung Techwin
Samsung
C&T
SamsungLife
Source: Woori I&S Research Center
8/2/2019 Focus on iVD
16/37
16
Bio/Healthcare www.wooriwm.com
IV. Changing domestic and global diagnostics market
1. Developed markets such as US, Europe leading global diagnostics industry
1.1. Diagnostics becomes new growth driver for global healthcare companies
MDx market to
expand at 2009~2013
CAGR of 15%
In 2008, the global IVD (in-vitro diagnostic) market grew more than 9.5% y-y to US$40bn.
In particular, the molecular diagnostic (MDx) market expanded from US$1bn in 2001 to
US$3bn in 2008. We expect the explosive growth of the global IVD market to continue as
technology advancesin 2013, we forecast that global IVD will reach US$53bn.
The major global players in IVD are Siemens, Roche Diagnostics, and Abbott Diagnostics,
and these three account for two thirds of the global market. In particular, Roche Diagnostics
is a leading player in genetic diagnostics, with a market share of more than 20%. While the
genetic diagnosis kit market is still small, we expect it to grow more than 15% per annum
going forward. In 2007, Roches IVD business generated US$7.8bn in sales, US$984mn of
which came from genetic diagnostic kits.
M&As to drive
growth of IVD
The big three in global IVD have grown through active M&As. For instance, Siemens
purchased Bayer Diagnostics for US$5.3bn, Dade Behring for US$6bn, and Diagnostic
Product Corporation for US$2bn, and these aggressive M&As helped Siemens emerge as a
strong player in IVD (with 35% market share). Meanwhile, Abbott added a strategic alliance
strategy to its M&A tactics to become a global IVD player. Abbott first entered the genetic
diagnostic market (breast cancer, colorectal cancer) by taking over Vysis for US$55mn in
2001. The technology and products secured via this M&A helped accelerate Abbotts growth
in diagnostics, as well as improve the IVD divisions operating margins (average 20%).
8/2/2019 Focus on iVD
17/37
17
Bio/Healthcare www.wooriwm.com
1.2. Direction of Techwins healthcare business: learn from Mindrays growth
Techwin should learn
from Mindrays
growth
Mindray is Chinas largest medical equipment maker and is listed on the Nasdaq. Since
listing, Mindray has received a premium relative to the market, and although the premium
narrowed from Oct 2008 amid the financial crisis, it has returned recently, with shares
Mindray shares outperforming the market.
Mindray makes patient-monitoring devices, IVD equipment, diagnostic kits, and visual
equipment at its China-based plant. The company has more than 1,500 R&D personnel and
six global R&D centers. It has been able to grow faster than competitors thanks to strong
price competitiveness, and showed steep growth in 2008 with the rollout of 10 new products.
Mindrays 2008 sales grew 87% y-y to US$548mn (up from US$294mn in 2007), and
operating margin remains over 20%.
Mindray receives 45% premium since financial crisis
-30
0
30
60
90
120
150
180
210
240
'06 '07 '08 '09
MSCI US healthcare premium relative to market
Mindray premium relative to market
(%)
Mindray received premium of 102% since
listing and 45% since financial crisis
Source: Woori I&S Research CenterNote: Acquired Datascope PMB(patient monitoring business) in March 2008
8/2/2019 Focus on iVD
18/37
18
Bio/Healthcare www.wooriwm.comPatient-monitor ing devices Hematology analyzers & reagents
Mindray
49%
Foreign
brands
34%
Other
domestic
17%
Mindray
39%
Otherdomestic
39%
Foreign
brands
22%
Source: Mindray, Woori I&S Research Center Source: Mindray, Woori I&S Research Center
Ultrasound systems Rapid growth in developed mkt: 15% in 2007 27% in 2008
Mindray
32%
Other
domestic
44%
Foreign
brands
24%
China
42 %
Developed
market
27 %
Emerging
market
19 %
Other
12 %
2008 sales: US$550mn
Source: Mindray, Woori I&S Research Center Source: Mindray, Woori I&S Research Center
Mindrays sales and net profit
0
20
40
60
80
100
120
140
2003 2004 2005 2006 2007 2008
0
7
14
21
28
35NP (LHS)
NP marg in (RHS)
($mn) (%)
CAGR 59.2%
Source: Mindray, Woori I&S Research Center
8/2/2019 Focus on iVD
19/37
19
Bio/Healthcare www.wooriwm.com
2. Domestic diagnostics overviewDomestic diagnostics
market boasts bright
growth prospects
There are only a few diagnostics makers in Korea. We believe the diagnostics market will
grow rapidly when life insurers go public.
Samsung Techwin should become the Samsung Groups medical equipment and diagnostics
arm. We expect it to enter the genetic diagnostics business in 2010 with the rollout of a blood
analysis device, polymerase chain reaction (PCR) device/reagent, and diagnostics kits (HBV,
HCV, AIDS). The company also has cancer diagnostic kits (breast, colon cancer) in its R&D
pipeline.
The method and application of diagnostics differ depending on the kind of sample used (eg,
urine, blood, genetic material). In terms of technology, genetic diagnostics requires more
advanced technology than urine diagnostics. Genetic diagnostics is classified into PCR/RT-
PCR (real-time PCR), sequencing, MS spectrometry, and microarray.
Classification by diagnostic method
Method Urine Blood Gene
Company SDSDInfopiaNanoen Tek
PCR/RT-PCR (Techwin, Bioneer)Sequencing (Macrogen)MS Spectrometry (GeneMatrix)Microarray
Source: Woori I&S Research Center
8/2/2019 Focus on iVD
20/37
20
Bio/Healthcare www.wooriwm.com
3. FDA approval to begin with 510k clearance
The US classifies medical devices according to potential risk to the human body, given the
wide range of devices and their close relationship to health.
In the US, several measures have been taken to improve safety. For example, under the FDAs
differentiated approval system (1976), medical devices are classified into three quality
categories, and good manufacturing practices (GMP) were implemented to control the quality
of medical devices. We also note that US accounts for 50% of the global medical equipment
market.
510k clearance key to
US exports
Exports of medical devices to the US require FDA approval, which is largely divisible into
two processes. Class I and II medical devices are subject to 510k clearance, while class III
(newly developed) must obtain premarket approval (PMA). Most medical devices
manufactured in Korea are subject to 510k clearance.
The FDA does not require clinical test data for 510k clearance (except in the cases of some
life-support devices) and focuses on whether imported devices are compatible with other
devices in use in the nation. In addition, it requires all medical device makers to follow GMP.
With the medical device industry emerging as one of the most promising high-end markets
for the 21st century, we believe Korean players will have to focus on product quality, in
addition to product development.
8/2/2019 Focus on iVD
21/37
21
Bio/Healthcare www.wooriwm.com
510k clearance process
Class 3
510k process
Sales
Existing medicaldevice maker
Salescontinued
Medical device makerdifferent from existing ones
New medical device makersimilar to existing ones
Potential medicaldevice maker
Sales continueduntil FDA asks for
PMA
510k applicationSales prohibited until
FDA approvalSales prohibited until
FDA approval
Sales continued untilFDA asks for PMA
Submission to FDA
PMS process
Class 1 & 2
Class 3Class 1 & 2
FDA
Sales (continued)
Source: Woori I&S Research Center
8/2/2019 Focus on iVD
22/37
Woori I&S does not have a stake greater than or equal to 1% in Samsung Techwin as of the preparation date. Woori I&S has not provided this material to an institutional investor or other third party in advance. The Korean version of this material was distributed on January 5, 2010. The analyst and his/her spouse do not own any securities of companies mentioned in this material as of the preparation date. Woori I&S is an issuer and LP (liquidity provider) of ELW taking Samsung Techwin as an underlying asset. This report correctly reflects the analysts opinion and was written without any external influence or intervention.
Maintain Buy with TP of W120,000
Our target is based on RIM (assuming market risk premium of 6.0%, risk-free
rate 4.0%, beta 1.0, COE 10.1%) and implies 31.9% upside (as of Jan 4).
Shares currently trade at a 2010 P/E of 17x, vs the Kospi average of 10x, but we
believe Techwin deserves a premium due to the following: 1) three-year EPS
growth of 37.1%, higher than peers; 2) takeover of SECs CCTV unit and
synergy with robotics; and 3) growth potential from robotics and healthcare.
2009 results: to miss consensus, but expected to turn around
2009 sales and operating profit estimated at W2,652.0bn (+13.3% y-y) andW214.0bn (+45.6% y-y), respectively. In particular, 4Q09 sales and operating
profit likely reached W715.0bn (TTP y-y) and W36.0bn (-26.0% y-y),
respectively, far below market consensus, due to:
1) bonus payments (additional W30bn);
2) shipment and ASP fall at the phone camera module business; and
3) excessive hopes for margin improvement from takeover of CCTV unit
(W185.7bn)
2010 sales and operating profit estimated at W3,237.0bn (+22.1% y-y) and
W255.0bn (+18.9% y-y), respectively
Entry into healthcare business promising
Large players such as the Samsung Group and SK Chemical are diversifyinginto healthcare/biotech. We expect domestic healthcare market to grow rapidly
Samsung likely to focus on medical equipment and genetic diagnostics
1) Samsung plans to launch blood analysis equipment in 2010 as well as
genetic diagnostics (PCR)/agent and diagnostic kits (HBV, HCV, AIDS)
2) Global IVD kit market to grow to US$52.0bn in 2013. PCR equipment
key to genetic diagnosis/diagnostic kitshas many applications, including
testing for diseases/food poisoning, and determining specific breeds.
Samsung Techwin(012450.KS)
Pr ime benef ic ia r y o f hea l thc areindus t r y g row th
Sales Chg OP Pre-tax NP EPS Chg P/E P/B EV/EBITDA ROE Debt/equity Net debtYE-Dec
(Wbn) (%) (Wbn) (Wbn) (Wbn) (won) (%) (x) (x) (x) (%) (%) (Wbn)
2007 3,243 13.1 170 232 203 2,638 28.7 19.2 3.9 12.8 21.7 85.1 -74
2008 2,340 -27.9 147 166 74 956 -63.8 35.8 2.5 9.5 7.0 121.0 -50
2009E 2,652 13.4 214 274 189 3,414 257.1 26.6 4.5 15.8 17.3 124.8 -96
2010F 3,237 22.1 255 316 278 5,232 53.2 17.4 3.6 13.2 22.6 119.0 -362
2011F 4,095 26.5 404 481 424 7,974 52.4 11.4 2.8 8.5 27.4 110.0 -677
Source: Woori I&S Research Center estimates
Buy(Maintain)
TP W120,000 (Maintain)
Sector Pharmaceutical/bio
Current price (01/04/10) W91,000
KOSPI 1,696.14
KOSDAQ 528.09
Market cap (common) $4,257.86mn
Outstanding shares (common) 53.1mn
Par value W5,000120DA trading vol 689,820 shrs
120DA share price W86,893
52W high (09/25/09) W104,500
Low (01/28/09) W30,250
Dividend yield (2008) 0.44%
Free float rate
Foreign ownership 16.7%
Major shareholders
SEC 25.5%
Mirae Asset Investment 11.0%
Stock performance (%)
3M 6M 12M
Absolute -11.5 -18.4 12.6
Relative -24.6 -43.6 -0.5
Analyst
Irene Kim822)768-7977, [email protected]
Young Park822)768-7585, [email protected]
8/2/2019 Focus on iVD
23/37
23
Samsung Techwin www.wooriwm.com
RIM valuation (Units: Wbn, won)
2009E 2010F 2011F 2012F 2013F 2014F 2015F 2016F 2017F 2018F 2019F 2020FNet profit 189 278 424 522 648 727 810 912 1,026 1,154 1,298 1,460
Shareholders equity 1,100 1,356 1,740 2,209 2,778 3,399 4,046 4,755 5,533 6,384 7,316 8,336
Forecast ROE (FROE) 17.3% 22.6% 27.4% 26.4% 26.0% 23.5% 21.8% 20.7% 19.9% 19.4% 18.9% 18.7%
Spread (FROE-COE) 7.2% 12.6% 17.3% 16.4% 15.9% 13.5% 11.7% 10.7% 9.9% 9.3% 8.9% 8.6%
Residual income 79 154 268 323 397 416 436 469 508 554 609 673
Cost of equity (COE) 10.1%
Beta 1.0
Market risk premium (Rm-Rf) 6.0%
Risk-free rate (Rf) 4.0%
Beginning shareholders equity 1,081.3
PV of forecast period RI 2,637.2
PV of continuing value 1,907.1
Equity value (C+P) 5,625.6
No of shares (common, mn) 53.1
12m TP
Fair price (C) 116,535
Current price (C) 91,000
Upside (-downside) 28.1%
Implied P/B (x) 4.6
Implied P/E (x) 22.3
Note: RIM (Residual Income Model) is a cash flow approach that yields a fair shareholder value (value of equity) by adding shareholders equity and present value of residualincome (meaning income excluding cost of equity).
Value of equity = shareholders equity + sum of present value of future residual income* Residual income (RIt) = NP (t) shareholders equity(t-1) * cost of equit y (t)= shareholders equity (t-1) * (ROEt - COEt)
Woori I&S uses RIM as our primary valuation model as RIM is an objective model that minimizes subjectivity of valuation indicators while producing same results as DDM(dividend discount model) and DCF.
Market risk premium assessment guidelines
Mega cap Large cap Mid cap Small cap
CriteriaMarket cap of W10tn or higher
+ credit rating of 'AAA' or higherMarket cap of W1~10tn
+ credit rating of 'A0' or higherMarket cap of W200bn-1tn
+ credit rating of 'BBB+' or higherMarket cap of less than W200bn+ credit rating of 'BBB-' or higher
Risk premium 5.2% 6.0% 7.0% 8.0%
* Risk Free Rate = 4.0%( standardized)
8/2/2019 Focus on iVD
24/37
24
Samsung Techwin www.wooriwm.com
Samsung Techwin: P/E band Samsung Techwin: Premium to the Kospi
0
20,000
40,000
60,000
80,000
100,000
'05.1 '06.1 '07.1 '08.1 '09.1 '10.1 '11.1
(Won) Price 17.0x
21.0x 24.0x
27.0x 33.0x
-100
0
100
200
300
400500
600
'04 '05 '06 '07 '08 '09 '10
Premium to the Kospi
305% premium since 2009on: 1) entry into heatlhcare;
2) takeover of CCTV unit; and
3) stable sales of defense unit
Source: Dataguide Pro, Woori I&S Research Center Source: Datastream, Woori I&S Research Center
Samsung Techwin: P/B band Diagnostics division earnings estimates
0
20,000
40,000
60,000
80,000
100,000
120,000
'05.1 '06.1 '07.1 '08.1 '09.1 '10.1 '11.1
(Won) Price 1.0x
2.5x 5.0x
6.0x 6.5x
0
10 0
20 0
30 0
40 0
50 0
60 0
70 0
80 0
90 0
3Q10F 4Q10F 1Q11F 2Q11F 3Q11F 4Q11F
0%
5%
10 %
15 %
20 %
25 %Sales
OP margin
(W100mn)
Source: Dataguide Pro, Woori I&S Research Center Source: Woori I&S Research Center
8/2/2019 Focus on iVD
25/37
25
Samsung Techwin www.wooriwm.com
Entry into diagnostics market
Prime beneficiary of
Samsung Groups
entry into
bio/healthcare
Techwin is likely to be the prime beneficiary of the Samsung Groups entry into
bio/healthcare business.
We believe the closest comparable for Techwin is Mindray. Established in 1991, Mindray
sells patient-monitoring equipment, IVD equipment, diagnostics kits, and imaging equipment.
It is Chinas largest medical equipment producer and has traded at lofty premiums to the
market since its listing on the Nasdaq. The company has more than 5,000 employees, with
more than 1,500 in R&D. The company operates six R&D centers worldwide.
We believe Samsung Techwin deserves a premium to the market for its entry into diagnostics
and medical equipment. Shares currently trade at a 2010 P/E of 17x. Valuations may look
burdensome given its heavy dependence on the defense and machinery divisions, however,
the company is making efforts to strengthen growth potential by entering the robotics and
healthcare industries. As an important part of the Samsung Groups healthcare business value
chain, we expect Techwin to enjoy synergies with group affiliates. In addition, the company islikely to enter overseas diagnostics markets, which offer lofty margins.
Samsung Techwin: medical equipmentdiagnostics
Life scienceIn-vitro
diagnosticsPharma
Genomics
Microarray Sequencing PCR
Development
Improve labefficiency
Develop new tests
Become pharmaplay via biodrugs
Biomarker expertise Develop new
bio drug
SMCSamsungTechwin
SEC/SMC
Increasingmedical value
to patients& physicians
Source: Woori I&S Research Center
8/2/2019 Focus on iVD
26/37
26
Samsung Techwin www.wooriwm.com
Investment points: maintain Buy with target price of W120,000
Prime beneficiary of
Samsung Groups
entry into healthcare
business
First, prime beneficiary of Samsung Groups entry into bio/healthcare business
Samsung Techwin is entering the healthcare industry in 2010 with the launch of itsdiagnostics business. In addition, we expect cash inflow of more than W300bn per annum
from 2010 thanks to stable results at the defense division. Techwin plans to pour cash into
new growth business such as healthcare, robotics, and FPSO (floating production, storage,
and offloading).
Security business
expansion
Second, takeover of SECs CCTV unit
Techwin announced in Oct 2009 that it would take over Samsung Electronics CCTV division
to strengthen Techwins security division. Going forward, we expect to see demand for
CCTVs from a variety of sources, including military applications. For example, Techwin
completed development of monitoring robot systems in a project for the Ministry of
Knowledge Economy in Nov 2008, and automated monitoring devices are slated to be used at
national borders and guard posts. Export is also a possibility, as there are currently no
monitoring systems with the range of features offered by Techwins products. In addition,
sales should see further demand for Koreas planned U-cities (ubiquitous city).
Stable revenue
sources
Third, stable revenue sources (power system and defense)
The power system and defense divisions bring in steady sales and profits regardless of
economic conditions.
8/2/2019 Focus on iVD
27/37
8/2/2019 Focus on iVD
28/37
8/2/2019 Focus on iVD
29/37
29
SD www.wooriwm.com
RIM valuation (Units: Wbn, won)
2009E 2010F 2011F 2012F 2013F 2014F 2015F 2016F 2017F 2018F 2019F 2020FNet profi t 31 38 43 49 56 65 71 79 88 97 107 119
Shareholders equity 78 115 156 203 258 321 390 464 544 631 725 827
Forecast ROE (FROE) 47.9% 39.1% 31.5% 27.5% 24.5% 22.3% 20.1% 18.5% 17.4% 16.5% 15.8% 15.3%
Spread (FROE-COE) 35.9% 27.1% 19.5% 15.5% 12.5% 10.3% 8.1% 6.5% 5.4% 4.5% 3.8% 3.3%
Residual income 23 26 26 28 29 30 29 28 27 27 26 26
Cost of equity (COE) 12.0%
Beta 1.0
Market risk premium (Rm-Rf) 8.0%
Risk-free rate (Rf) 4.0%
Beginning shareholders equity 49.4
PV of forecast period RI 186.0
PV of continuing value 35.2
Equity value (C+P) 270.7
No of shares (common, mn) 8.012m TP
Fair price (C) 37,896
Current price (C) 32,300
Upside (-downside) 17.3%
Implied P/B (x) 2.7
Implied P/E (x) 8.0
Note: RIM (Residual Income Model) is a cash flow approach that yields a fair shareholder value (value of equity) by adding shareholders equity and present value of residualincome (meaning income excluding cost of equity).
Value of equity = shareholders equity + sum of present value of future residual income* Residual income (RIt) = NP (t) shareholders equity(t-1) * cost of equity (t)= shareholders equity (t-1) * (ROEt - COEt)
Woori I&S uses RIM as our primary valuation model as RIM is an objective model that minimizes subjectivity of valuation indicators while producing same results as DDM(dividend discount model) and DCF.
Market risk premium assessment guidelinesMega cap Large cap Mid cap Small cap
CriteriaMarket cap of W10tn or higher
+ credit rating of 'AAA' or higherMarket cap of W1~10tn
+ credit rating of 'A0' or higherMarket cap of W200bn-1tn
+ credit rating of 'BBB+' or higherMarket cap of less than W200bn+ credit rating of 'BBB-' or higher
Risk premium 5.2% 6.0% 7.0% 8.0%
* Risk Free Rate = 4.0%( standardized)
P/E band P/B band
0
10,000
20,000
30,000
40,000
50,000
'05.1 '06.1 '07.1 '08.1 '09.1 '10.1 '11.1
(Won) Price 7.0x
14.0x 21.0x
28.0x 35.0x
0
10,000
20,000
30,000
40,000
50,000
'05.1 '06.1 '07.1 '08.1 '09.1 '10.1 '11.1
(Won)
Price 1.5x
3.0x 4.5x
5.0x 6.0x
Source: Dataguide Pro, Woori I&S Research Center Source: Dataguide Pro, Woori I&S Research Center
8/2/2019 Focus on iVD
30/37
30
SD www.wooriwm.com
Likely to rol l out rapid test kits in developed marketsSD to roll out rapid
test kits in developed
markets
SD is a specialized virus diagnostics company, with a flagship business of blood-based rapid
test kits. Rapid test kits detect antigens and antibodies related to certain illnesses, and are
used in diagnosing AIDS, malaria, and hepatitis. The company is capable of manufacturing
antigens and antibodies (the raw materials for test kits) internally, demonstrating itstechnological prowess and giving it an edge in pricing. SD posted 2005~2008 sales and
operating profit CAGRs of 49% and 72%, respectively.
The companys 2008 sales broke down as: rapid test kits 76.5%, urine chemical analysis
3.9%, ELISA 2.2%, and bio sensors 4.6%. We expect the sales contribution of new bio
sensors to increases, diversifying the companys earnings sources, as rapid test kits and bio
sensors are expected to become major businesses. Going forward, we believe SD will emerge
as a major player in POCT (point-of-care testing).
Operating profit and
margin to improvesharply
We believe the rapid test kit divisions 2009 sales surged 79.4% y-y to W51.0bn. We estimate
2009 sales and operating profit at W64.3bn (+59.3% y-y) and W29.1bn (+105.2% y-y),respectively, showing a sharp improvement in margins. We believe 2009 earnings will
substantially beat company guidance (sales W60.0bn, operating profit W21.0bn) on: 1)
growing export of new malaria and dengue fever diagnostic kits; and 2) a sharp increase in
domestic AH1N1 diagnostic kit sales, leading to growing sales of rapid test kits and
subsequently stronger margins. Meanwhile, we estimate 2010 sales and operating profit at
W82.4bn (+28.3% y-y) and W34.8bn (+19.3% y-y), respectively, on the entry of flagship
AIDS test kits into developed markets and the high growth of Indias rapid-test-kit market.
Sales and operating profit to sustain high growth on entry into developed market
0
20
40
60
80
100
2006 2007 2008 2009 2010F 2011F
(Wbn)
0
10
20
30
40
50
(%)Sales (LHS)
OP (LHS)
OP marg in (RHS)
79.5%
80.0%83.7%76.6%
86.2%
0
20
40
60
80
100
2007 2008 2009 2010 2011
(Wbn)
Rapid ELISA
Urine Bio sensor
Raw material and other
Source: SD, Woori I&S Research Center Source: SD, Woori I&S Research Center
8/2/2019 Focus on iVD
31/37
31
SD www.wooriwm.com
Investment points: initiate coverage at Buy with target price of W38,000Leading player in
rapid test kits
First, SD is a leading player in rapid test kits.
SD is a specialized virus diagnostics company, with a flagship business of blood-based rapid
test kits. Rapid test kits detect antigens and antibodies related to certain illnesses, and areused in diagnosing AIDS, malaria, and hepatitis. The company is capable of manufacturing
antigens and antibodies (the raw materials for test kits) internally, demonstrating its
technological prowess and giving it an edge in pricing. SD posted 2005~2008 sales and
operating profit CAGRs of 49% and 72%, respectively.
Likely to enter
developed markets
Second, SD to enter developed market following expiry of Inverness patent.
SD has been unable to enter the AIDS test kit market in US, Europe, and Japan due to
competition with Inverness. However, Inverness patent will expire in 2010, and we believe
this will allow SD to sell its rapid test kits in developed markets (eg, Japan and Europe).
Plans to entermolecular
diagnostics
Third, R&D to yield tangible results, easing entry into biochips, molecular diagnostics
SD plans to enter the biochip and molecular diagnostic markets, which are rapidly growing
segments of the IVD industry. Existing rapid test kits have qualitative limitations, as they are
only able to determine whether a virus/target exists. In contrast, biochips and gene
diagnostics offer quantitative analysis, allowing the measurement of the progress of a disease
and monitoring of post-operative condition. SD is making efforts to roll out diagnostic chips
that can detect five major cancers and cardiovascular disease, by investing in new businesses.
Inverness flagship business: diagnostics reagent and kit
Diagnostics
63%
Other
37%
Diagnostics unit contribute 63% of 2008 sales
(totaling US$1.7bn). Inverness' patent for AIDS test
kits expired in Europe and Japan in 2 009.
SD likely to en ter develope d markets
Source: Bloomberg, Woori I&S Research CenterNote: Inverness asked SD for tender offer in 2009
8/2/2019 Focus on iVD
32/37
32
SD www.wooriwm.com
INCOME STATEMENT VALUATION INDEX
(Wbn) 2009/12E 2010/12F 2011/12F 2012/12F 2009/12E 2010/12F 2011/12F 2012/12FSales 64.3 82.4 89.4 99.8 EV/ EBITDA (X) 7.0 5.3 3.9 2.5
Growth (%) 59.3 28.3 8.5 11.6 EV/ EBIT (X) 7.6 5.6 4.2 2.7
Cost of sales 21.7 27.3 29.6 33.0 Price/ Earning (FD) (X) 8.3 6.9 6.1 5.2
Gross prof it 42.6 55.2 59.8 66.8 Adjusted PER (X) 8.3 6.9 6.1 5.2
Gross margin (%) 66.3 66.9 66.9 66.9 Price/ Gross Cash Flow (X) 7.7 6.4 5.7 5.0
SG&A 13.5 20.4 22.1 24.6 Price/ Book Value (X) 3.3 2.3 1.7 1.3
EBITDA 31.6 37.3 40.3 44.9 Price/ Sales (X) 4.0 3.1 2.9 2.6
EBITDA margin (%) 49.2 45.2 45.0 45.0 PER/ EPS growth (X) 0.5 0.5 0.4 na
Depr & amort 2.5 2.5 2.6 2.7 PER/ EBITPS growth (X) 0.6 0.7 0.5 na
Operating profit 29.1 34.8 37.7 42.2 PER/ EBITDAPS growth (X) 0.7 0.7 0.6 na
OP margin (%) 45.3 42.2 42.2 42.3 Enterprise Value (Wbn) 222.6 195.8 157.4 113.6
Non-operating Income 1.2 2.6 4.5 6.7 EPS CAGR (3-Yr, FD) (%) 17.2 14.4 14.9 na
Non-operating Expenses 0.0 0.0 0.0 0.0 EBITPS CAGR (3-Yr, FD) (%) 13.1 10.3 11.1 na
Net interest inc/ (exp) 1.2 2.6 4.4 6.7 EBITDAPS CAGR (3-Yr, FD) (%) 12.4 9.9 10.8 na
Pre-tax Profit from Continuing Operations 30.3 37.3 42.1 48.8 EBITPS (FD) (W) 3,642 4,345 4,714 5,273
Pretax margin (%) 47.2 45.3 47.1 49.0 EBITDAPS (FD) (W) 3,951 4,658 5,035 5,607
Tax -0.3 -0.4 -0.4 -0.5 Fully diluted EPS (W) 3,828 4,713 5,319 6,165
Profit from Continuing Operations 30.6 37.7 42.6 49.3 Adjusted EPS (FD) (W) 3,828 4,713 5,319 6,165
Net profit 30.6 37.7 42.6 49.3 CFPS (W) 4,139 5,027 5,641 6,499
Net margin (%) 47.7 45.7 47.6 49.4 BVPS (W) 9,601 14,146 19,294 25,287
Adjusted Net Profi t 30.6 37.7 42.6 49.3 Sales PS (W) 8,033 10,304 11,178 12,471
CASH FLOW STATEMENT RIM & EVA
(Wbn) 2009/12E 2010/12F 2011/12F 2012/12F 2009/12E 2010/12F 2011/12F 2012/12FOperating Cash Flow 21.8 31.6 41.8 47.1 RIM
Net profit 30.6 37.7 42.6 49.3 Spread (FROE-COE) (%) 35.9 27.1 19.5 15.5
+ Depr & amort 2.5 2.5 2.6 2.7 Residual Income 23.0 26.1 26.3 27.8
+ Associates loss (-profits) 0.0 0.0 0.0 0.0 12M RIM-based Target Price(W) 37,848
+ FC translation loss (-profit) 0.0 0.0 0.0 0.0 Economic Value Added
+ Loss (-gain) on tangible asset disp 0.0 0.0 0.0 0.0 Invested capital 42.3 48.7 51.4 55.4
Gross Cash Flow 33.1 40.2 45.1 52.0 NOPAT 29.4 35.1 38.1 42.6
- Incr (+dec) in working capital -11.3 -8.6 -3.3 -4.9 ROIC (%) 76.7 77.2 76.2 79.8
Invest ing Cash Flow -3.0 -3.4 -3.1 -3.6 ROIC - WACC (%) 68.5 68.8 67.8 71.4
Decr. in Tangible Assets 0.0 0.0 0.0 0.0 EVA 29.0 33.5 34.8 39.6Incr. in Tangible Assets (CAPEX) -2.1 -2.6 -2.9 -3.2 Discounted Cash Flow
+ Disp (-acq) of inv assets 0.0 0.0 0.0 0.0 EBIT 29.1 34.8 37.7 42.2
Free Cash Flow 19.7 29.0 39.0 43.9 + Depreciation 2.5 2.5 2.6 2.7
Net Cash Flow 18.8 28.2 38.7 43.5 - CAPEX 2.1 2.6 2.9 3.2
Financing Cash Flow 2.5 1.5 1.5 -1.5 Free cash flow for DCF valuation 22.3 29.2 35.6 38.8
Equity financing 0.0 0.0 0.0 0.0 Weighted Average Cost of Capital (%)
Debt financing 2.5 1.5 1.5 -1.5 Cost of debt (tax adjusted) 4.4 4.1 4.0 3.9
+ Inc (-dec) in Cash & St. financial goods 21.2 29.7 40.1 42.0 Cost of equity (COE) 12.0 12.6 12.7 12.8
Net debt/(cash) end -32.6 -62.6 -101.0 -144.8 WACC 8.2 8.4 8.3 8.4
BALANCE SHEET PROFITABILI TY & STABIL ITY
(Wbn) 2009/12E 2010/12F 2011/12F 2012/12F 2009/12E 2010/12F 2011/12F 2012/12FCash & St. Financial Goods 33.1 63.0 101.4 145.1 ROE (%) 47.9 39.1 31.5 27.5
Accounts Receivable 28.3 36.3 39.4 44.0 ROA (%) 38.3 31.8 26.4 23.7
Total current assets 71.9 112.7 155.2 205.2 ROIC (%) 76.7 77.2 76.2 79.8Tangible Assets 18.8 19.1 19.5 20.2 EBITDA/ equity (%) 40.3 32.5 25.9 22.1
Investment assets 5.2 5.6 5.8 6.0 EBITDA/ asset (%) 32.3 26.7 22.1 19.2
Non-cur rent Assets 26.1 26.7 27.2 28.0 Dividend Yield (%) 0.6 0.6 0.6 0.6
Total Asset 97.9 139.4 182.4 233.2 Cash dividends(Wbn) 1.5 1.5 1.5 1.5
Short-term debt 0.3 0.3 0.3 0.3 Cash DPS (W) 200 200 200 200
Accounts Payable 5.7 7.3 7.9 8.8 Net debt(cash)/ equity (%) -41.6 -54.6 -64.9 -71.2
Total current Liabili ties 18.6 23.8 25.8 28.8 Debt/ equity (%) 24.9 21.7 17.3 14.7
Long-term debt 0.6 0.6 0.6 0.6 Net interest exp/ sales (%) -1.9 -3.1 -5.0 -6.7
Long-term allowance 0.0 0.0 0.0 0.0 Interest coverage (X) -24.5 -13.5 -8.5 -6.3
Non-current Liabili ties 0.9 1.0 1.0 1.1 Current Ratio (%) 385.4 472.5 600.7 712.5
Total Liabi li ties 19.5 24.8 26.9 29.9 Quick Ratio (%) 343.9 430.9 559.0 670.8
Paid-in Capital 4.0 4.0 4.0 4.0 Total shares (mn) 8 8 8 8
Capital surplus 18.8 18.8 18.8 18.8 Par value (W) 500 500 500 500
Retained earnings 58.8 95.0 136.0 183.8 Share price (W) 31,900 32,300 32,300 32,300
Total shareho lder s Equity 78.4 114.6 155.6 203.4 Market cap (Wbn) 255 258 258 258
8/2/2019 Focus on iVD
33/37
Woori I&S does not have a stake greater than or equal to 1% in Macrogen as of the preparation date. Woori I&S has not provided this material to an institutional investor or other third party in advance. The Korean version of this material was distributed on January 5, 2010. The analyst and his/her spouse do not own any securities of companies mentioned in this material as of the preparation date. Macrogen is not under coverage at Woori I&S. Thus, Woori I&S does not present a rating and target price on the counter. This report correctly reflects the analysts opinion and was written without any external influence or intervention.
Competitive in genetic analysis
Leader in genomics-based preventive medicine.
Completion of Human Genome Project in 2007 offers new paradigm for
information medicine.
2QFY09 earnings to be in line with 1QFY09
We expect 2QFY09 sales (October~December, fiscal year ends June) of
W5.8bn (down 6.4% y-y, up 0.1% q-q) and operating profit of W300mn (up
2.4% y-y and 0.5% q-q).
Sales break down as: gene analysis 84%, biochips 11%, and transgenic mice
(5%). Exports account for 65% of sales.
Despite the steady rise in the sequencing business, sales slowed due to:
1) falling won/dollar rates (although sales volume increased)
2) stiff competition in sequencing overseas amid rise in personalized medicine
Leader in consumer genomics
Genomic medicine is the fundamental basis for personalized medicine.
Although the price tag for a personal genome analysis in 2000 would have
come to more than US$3bn, we expect the price to fall to only US$1,000 in
2010 thanks to improvements in sequencing devices.
Macrogen is the largest shareholder of US-based sequencing device developerLightSpeed, with a 25% stake (including stakes held by Macrogen subsidiaries)
The personalized medicine market should grow at a 2008~2013 CAGR of
more than 11% (up from US$232bn in 2009)
Since investing in LightSpeed, Macrogen has become more competitive in
personalized preventive medicine. Share price will likely rise further as
personalized medicine grows.
Macrogen(038290.KQ) Leader in consumer genomic s
Sales Chg OP Pre-tax NP EPS Chg P/E P/B EV/EBITDA ROE Debt/equity Net debtYE-Jun
(Wbn) (%) (Wbn) (Wbn) (Wbn) (won) (%) (x) (x) (x) (%) (%) (Wbn)
2008 16.5 31.1 -1.1 0.2 0.2 35 TTP 268.2 1.5 18.0 0.5 10.0 -10.0
2009 22.5 36.0 1.6 3.3 3.3 653 1763.9 27.8 2.7 19.1 9.7 14.0 -7.1
2010E 25.9 15.1 1.3 - 3.0 600 -8.1 21.5 - - - - -
2011F 33.7 30.1 2.4 - 4.0 800 33.3 16.2 - - - - -
Source: Macrogen, Woori I&S Research Center estimates
Not RatedAnalyst
Irene Kim822)768-7977, [email protected]
Susie Lee (RA)822)768-7646, [email protected]
Sector Pharma/bio
Current price (01/04/10) W12,900
KOSPI 1,696.14
KOSDAQ 528.09
Market cap (common) $56.89mn
Outstanding shares (common) 5.0mn
Par value W500
120DA trading vol 62,848 shrs
120DA share price W14,38552W high (09/04/27) W22,700
Low (09/01/21) W8,560
Dividend yield (2008) 0.0%
Free float
Foreign ownership 0.1%
Major shareholders
Jungsun Seo 8.0%
Hanmi Gross Equity Investment Union 4.6%
Share performance (%)
3M 6M 12M
Absolute -3.7 -38.6 50.2Relative -8.8 -43.8 -5.3
8/2/2019 Focus on iVD
34/37
34
Macrogen www.wooriwm.com
Leader in consumer genomics
Cheaper genetic
analysis to help
bolster personalized
medicine
Listed in 2000, Macrogen is a genetic analysis specialist and exports to 60 countries. The
completion of the Human Genome Project in 2007 offered a new paradigm for information
medicine, and Macrogen should be able to take the lead in personalized medicine.
Genomic medicine is the fundamental basis for personalized medicine. Macrogen provides
personalized services (including genetic database services), and makes bio diagnostic chips.
Although the price tag for a personal genome analysis in 2000 would have been more than
US$3bn, we expect the price to fall to only US$1,000 in 2010 thanks to improvements in
sequencing devices. Cheaper genetic analysis should help grow the personalized medicine
market at a 2008~2013 CAGR of more than 11% (up from the current market size of
US$232bn in 2009).
Macrogen is the largest shareholder of US-based sequencing device developer LightSpeed,with a 25% stake (including stakes held by Macrogen subsidiaries). Since investing in
LightSpeed, Macrogen has become more competitive in personalized preventive medicine.
Share price will likely rise further as personalized medicine grows.
8/2/2019 Focus on iVD
35/37
Woori I&S does not have a stake greater than or equal to 1% in Bioneer as of the preparation date. Woori I&S has not provided this material to an institutional investor or other third party in advance. The Korean version of this material was distributed on January 5, 2010. The analyst and his/her spouse do not own any securities of companies mentioned in this material as of the preparation date. Bioneer is not under coverage at Woori I&S. Thus, Woori I&S does not present a rating and target price on the counter. This report correctly reflects the analysts opinion and was written without any external influence or intervention.
Genetic diagnostics business growing rapidly
Bioneer specializes in the production of genetic diagnostic equipment and kits,
and research diagnosis equipment
Since the breakout of AH1N1 in 2009, there has been strong demand for
genetic diagnostic tools, which have been distributed to major general hospitals
and public clinics in Korea. Bionner has sold 30 units of gene diagnosis
equipment (totaling W2.6bn) to the Seoul metropolitan government.
2009 preview: operating profit to turn positive
We expect Bioneer to post 2009 sales of W28.8bn (up 93.2% y-y) and operating
profit of W7.2bn (TTP, y-y). In particular, we believe 4Q09 sales were a
record-high (since listing) thanks to growing sales of diagnosis equipment and
test kits related to the AH1N1 virus.
Strong sales and operating profit are attributed to:
1) large-scale margin improvement on diagnostic equipment and kit sales
(W9bn) related to AH1N1; and
2) falling cost-to-sales ratio on growing sales contribution from high-margin
genetic diagnostic kits and equipment, and even distribution of fixed costs.
Advancing into overseas markets
The global IVD kit market expected to grow to US$5.2bn in 2013 (2003~2013
CAGR of 9%). PCR equipmentkey to genetic diagnosis/diagnostic kitshas
many applications, including testing for diseases and food poisoning and
determining the specific breed of a species
Rapid change expected in domestic healthcare market in 2010, triggered by the
entry of the Samsung Group, led by Samsung Techwin
We expect Bioneer to grow, driven by the rapidly expanding genetic and other
diagnostic kit businesses. Excluding the temporary sales spike from AH1N1 in
2009, 2010 sales and operating profit should rise 14.6% and 61.1% y-y,
respectively, to W33bn and W11.6bn
Major share price catalysts for Bioneer are sales growth of diagnostic tests and
kits (given the expansion of the diagnostic test market in the aftermath of the
AH1N1 virus breakout) and diagnostic divisions entry into overseas markets
Bioneer(064550.KQ)
Foc us on h igh mar g ins ind iagnos t i cs
Sales Chg OP Pre-tax NP EPS Chg P/E P/B EV/EBITDA ROE Debt/equity Net debtsYE-Dec
(Wbn) (%) (Wbn) (Wbn) (Wbn) (won) (%) (x) (x) (x) (%) (%) (Wbn)
2007 12.5 7.7 -2.3 -6.3 -6.3 -559 RR NA 1.4 136.0 -16.3 52.1 7
2008 14.9 19.3 -0.3 -3.6 -3.6 -314 RR NA 0.8 11.8 -10.1 73.5 13
2009E 28.8 93.3 7.2 - 6.2 564 TTP 10.8 - - - - -
2010F 33.0 14.6 8.5 - 7.3 664 17.7 9.2 - - - - -
Source: Bioneer, Woori I&S Research Center estimates
Analyst
Irene Kim822)768-7977, [email protected]
Susie Lee (RA)822)768-7646, [email protected]
Sector Pharm/bio-tech
Current price (01/04/19) W5,900
KOSPI 1,696.14
KOSDAQ 528.09
Market cap (common) $59mn
Outstanding shares (common) 11.0mn
Par value W500
120DA trading vol. 414,790shrs
120DA share price W5,021
52W high (08/28/09) W7,910
Low (01/15/09) W1,500
Foreign ownership (2008) 0.00%
Free float rate
Foreign ownership 0.1%
Major shareholders
Han-oh Park 25.2%
Dae-sil Lee 5.2%
Share performance (%)
3M 6M 12M
Absolute 21.3 40.6 268.8
Relative 16.2 35.4 213.3
Not Rated
8/2/2019 Focus on iVD
36/37
Woori I&S does not have a stake greater than or equal to 1% in Infopia as of the preparation date. Woori I&S has not provided this material to an institutional investor or other third party in advance. The Korean version of this material was distributed on January 5, 2010. The analyst and his/her spouse do not own any securities of companies mentioned in this material as of the preparation date. Infopia is not under coverage at Woori I&S. Thus, Woori I&S does not present a rating and target price on the counter. This report correctly reflects the analysts opinion and was written without any external influence or intervention.
Core product is blood glucose bio sensor kit (diabetes)
Infopias core product is a blood-glucose bio sensor kit for diabetes diagnosis.
In line with the aging society, diagnostic kit market becoming increasingly
important within healthcare industry. However, Infopias global market share
has not risen much yet due to weak overseas marketing capability.
2009 preview: results likely to fall short of market consensus
Infopia is expected to post 2009 sales of W41bn (up 10.2% y-y) and net profit
of W8.9bn (up 58.9% y-y), falling far short of company guidance (sales of
W55bn, net profit of W14.4bn).
Disappointing earnings are attributed to: 1) weak sales of HbA1C equipment
(sales originally estimated at W10bn or more) due to defects; and 2) delayed
sales in US to improve accounts receivable turnover in US market
Time to move aggressively overseas
Given increasing number of diabetes patients worldwide (170mn in 2000 to
370mn in 2030, according to WHO), the global market for blood-glucose
diagnosis kits is expected to surge. In addition, the listing of life insurers should
increase demand for blood-glucose test kit and bio sensors, which are simple,
cost-effective ways for individuals to monitor their condition
Infopia has made efforts to diversify its product portfolio to lower its
dependence on one item (blood-glucose test biosensor), but in the process, its
HbA1C equipment (blood glucose test equipment for hospitals) was found to
have defects. However, its efforts to diversify its product portfolio (cholesterol/
liver disease diagnosis sensor, heart disease diagnosis sensor) will continue in
line with efforts to strengthen future growth potential.
While Infopia is known to have both earnings stability and sound growth
potential, potential investors should keep a close eye on intensifying
competition in the domestic market and its weakness in overseas markets.
Infopia(036220.KQ) Qual i ty h igh , bu t m arket ing w eak
Sales Chg OP Pre-tax NP EPS Chg P/E P/B EV/EBITDA ROE Debt/equity Net debtsYE-Dec
(Wbn) (%) (Wbn) (Wbn) (Wbn) (won) (%) (x) (x) (x) (%) (%) (Wbn)
2007 31.2 50.5 8.4 10.8 8.8 1,271 36.5 32.3 6.8 30.1 30.3 14.0 -11.8
2008 37.2 19.4 11.2 7.6 5.6 747 -41.2 15.1 1.9 6.6 12.0 24.9 1.6
2009E 41.0 10.2 10.5 - 8.9 1,271 70.1 12.3 - - - - -
2010F 53.5 30.5 14.4 - 12.2 1,743 37.1 9.0 - - - - -
Source: Infopia, Woori I&S Research Center estimates
Analyst
Irene Kim822)768-7977, [email protected]
Susie Lee (RA)822)768-7646, [email protected]
Not Rated
Sector Pharm/bio-tech
Current price (01/04/10) W14,700
KOSPI 1,696.14
KOSDAQ 528.09
Market cap (common) $96.26mn
Outstanding shares (common) 7.4mn
Par value W500
120DA trading vol. 162,446shrs
120DA share price W13,219
52W high (05/19/09) W22,305
Low (11/03/09) W10,041Dividend yield (2008) 0.68%
Free float rate
Foreign ownership 12.1%
Major shareholders
Byung-woo Bae 12.9%
Sei Asset Korea 4.6%
Share performance (%)
3M 6M 12M
Absolute 24.1 -19.5 26.8
Relative 19.0 -24.7 -28.6
8/2/2019 Focus on iVD
37/37
Bio/Healthcare www.wooriwm.com
Rating and Target Price Update
Company Code Date Company Code
Samsung Techwin 012450.KS 2009.11.02 Buy W120,000 (12M)
2009.09.14 Buy W110,000 (12M)
2009.05.25 Buy W89,000 (12M)
2009.04.20 Buy W65,000 (12M)2009.03.17 Buy W46,000 (12M)
2009.02.23 Buy W42,000 (12M)
2008.11.11 Buy W42,000 (12M)
2008.10.21 Buy W33,000 (12M)
0
50,000
100,000
150,000
'08.1 '08.4 '08.7 '08.10 '09.1 '09.4 '09.7 '09.10
Closing price
Target price (12M)
(won)
Company Code Date Company Code
SD 066930.KS 2010.01.05 Buy W38,000 (12M)
010,000
20,000
30,000
40,000
50,000
'08.1 '08.4 '08.7 '08.10 '09.1 '09.4 '09.7 '09.10
Closing price
Target price (12M)
(won)
WOORI Investment & Securities s tock ratings
1. Period: Uniform 12-month2. Rating System: Based on a stocks absolute return from the date of publication,
Strong Buy: high conviction Buy rated stocks Buy: greater than +15% Hold: 0% and +15% Reduce: less than 0%
The research is based on current public information that Woori I&S considers reliable, but Woori I&S does not represent it asaccurate or complete and it should not be relied on as such. Furthermore, the research does not take into account particularinvestment objectives, financial situations or individual client needs, and Woori I&S is in no way legally responsible for futurereturns or loss of original capital. All materials in this report are the intellectual property of Woori I&S. Copying, distributing,transmitting, transforming or lending of this material without Woori I&S' consent is prohibited.